COVID-19 / Spain’s PharmaMar to Begin Trials for Aplidin
PharmaMar, a Spanish firm, is beginning Phase II clinical trials for its anti-tumour drug Aplidin to treat coronavirus. The firm’s stocks have soared on the news. PharmaMar is joining…
Research in neuroscience has a longstanding tradition in Spain mostly inspired by Nobel Prize winner Santiago Ramón y Cajal and his disciples, for whom the “Instituto Cajal” (IC) was initially conceived in 1934. Five years later the Spanish Government created the National Research Council under the name of Consejo Superior de Investigaciones Cientificas (CSIC) and the IC became one of the first centers of this new Institution. The IC is one of the two CSIC centers fully devoted to research in Neuroscience. The Institute moved to its present location in downtown Madrid in a building of 4,500 m2 in 1989. Currently the IC houses 25 independent research teams and around 200 staff, with operating costs close to 9 K€/year.
From its inception the Cajal Institute has contributed to the advance in Neuroscience and has hosted and formed many of the neuroscientists working now in the different Spanish research and academic centers. Along almost one century of life, the Institute has become a center of worldwide reputation, building on the important contributions of its founder to the present day. Current staff of the Institute has been selected under a tight competitive system according to the high standards of the CSIC. Presently, the institute is organized in two departments: Functional and Systems Neurobiology, and Cellular, Molecular and Developmental Neurobiology, which intend to agglutinate research in all major areas of neuroscience. The focus of the IC research can be comprised in five major lines:
– Mechanisms of neural specification
– The neuro-vascular unit
– Processing of neural signals (a new line of work in neuro-prosthetics and bioengineering is being planned to be incorporated in the near future to reinforce this section)
– Neuroprotection and regeneration
– Systemic modulators of brain function
Contact information:
Cajal Institute (CSIC)
Avenida Doctor Arce 37
28002 Madrid.
PharmaMar, a Spanish firm, is beginning Phase II clinical trials for its anti-tumour drug Aplidin to treat coronavirus. The firm’s stocks have soared on the news. PharmaMar is joining…
Building on the topics covered in our March 2019 report, the latest edition of Healthcare & Life Sciences Review Spain takes a closer look at the broader Spanish life sciences…
Juan Carlos Moro Rodríguez, CEO for the Iberia Cluster with DB Schenker, discusses the company’s plans to expand its reach across all forms of transport, offering logistics solutions rather than…
Though still one of the younger and lesser-known outfits inhabiting the European drug development landscape, Irish-headquartered rare disease specialist, Jazz pharma has been making tremendous headway in the onco-haematology and…
In what is a highly competitive and crowded women’s health field in Spain, smaller players are having to be increasingly focused and specialised to carve out a market share. …
Many of the world’s mega-rich are increasingly active philanthropists in the healthcare arena and Spain is no exception with Galician billionaire Amancio Ortega Gaona, the 82-year-old owner of clothing empire…
The global acquisition of GSK’s thrombosis portfolio and subsequent purchase of AstraZeneca’s anaesthesia business have been critical milestones for the maverick South African pharmaceutical outfit Aspen, enabling the company to…
Perhaps the only CEO of a dermo-cosmetics company with a PhD in astrophysics and space technology as well as three years working at NASA under his belt, Isdin’s Juan Naya…
The North-Eastern region of Catalonia is one of Spain’s most prosperous and has been allocating increasingly large amounts of its budget towards healthcare. With strong government backing and a robust…
Rocco De Bernardis, managing director for Johnson & Johnson Medical Devices in Spain offers his insights into the company’s local footprint, assesses the situation for value-based healthcare implementation in Spain…
Through a merger between INC Research and inVentiv Health in 2018, Syneos Health has become the industry’s only fully integrated biopharmaceutical solutions organisation which includes one of the world’s top…
Stefanie Granado, director general of Takeda Iberia recounts the opportunities available for Takeda in Spain following its acquisition of Shire. She also discusses Takeda’s local acquisition of TiGenix, handing Takeda…
See our Cookie Privacy Policy Here